Caris Life Sciences, Inc. (NASDAQ:CAI) Stock Has Average Target Price of $27.82 According to Analysts

Caris Life Sciences, Inc. (NASDAQ:CAI) has been given a consensus recommendation of “Moderate Buy” by the fourteen research firms that are currently covering the company, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and eight have assigned a buy recommendation to the company. The average 12 month price objective among brokers that have updated their coverage on the stock in the last year is $28.55.

A number of equities research analysts have recently commented on CAI shares. UBS Group initiated coverage on shares of Caris Life Sciences in a report on Wednesday, September 9th. They issued a “neutral” rating and a $28.00 target price for the company. Wall Street Zen raised Caris Life Sciences from a “sell” rating to a “hold” rating in a report on Sunday, August 16th. TD Cowen raised their price target on Caris Life Sciences from $30.00 to $36.00 and gave the stock a “buy” rating in a report on Tuesday, October 13th. Canaccord Genuity Group boosted their price target on Caris Life Sciences from $22.00 to $30.00 and gave the company a “hold” rating in a research report on Monday. Finally, BTIG Research upped their price objective on Caris Life Sciences from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Thursday, August 6th.

Insider Buying and Selling at Caris Life Sciences

In other news, insider John Russel Denton sold 7,500 shares of the business’s stock in a transaction that occurred on Tuesday, September 22nd. The stock was sold at an average price of $31.82, for a total value of $238,650.00. Following the transaction, the insider owned 174,855 shares of the company’s stock, valued at approximately $5,563,886.10. The trade was a 4.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, President David Spetzler sold 478,000 shares of the business’s stock in a transaction that occurred on Thursday, September 3rd. The shares were sold at an average price of $24.86, for a total value of $11,883,080.00. Following the completion of the transaction, the president directly owned 1,052,083 shares in the company, valued at approximately $26,154,783.38. The trade was a 31.24% decrease in their position. The disclosure for this sale is available in the SEC filing. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 1,004,712 shares of company stock worth $27,205,419. 50.00% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Caris Life Sciences

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. GAMMA Investing LLC raised its position in Caris Life Sciences by 133.0% during the 3rd quarter. GAMMA Investing LLC now owns 1,263 shares of the company’s stock worth $39,000 after buying an additional 721 shares during the last quarter. Sterling Capital Management LLC lifted its stake in shares of Caris Life Sciences by 128.3% in the 1st quarter. Sterling Capital Management LLC now owns 1,927 shares of the company’s stock worth $34,000 after acquiring an additional 1,083 shares during the period. PNC Financial Services Group Inc. lifted its stake in shares of Caris Life Sciences by 839.4% in the 1st quarter. PNC Financial Services Group Inc. now owns 1,644 shares of the company’s stock worth $29,000 after acquiring an additional 1,469 shares during the period. PEAK6 LLC boosted its holdings in shares of Caris Life Sciences by 6.9% in the fourth quarter. PEAK6 LLC now owns 24,800 shares of the company’s stock valued at $669,000 after acquiring an additional 1,600 shares in the last quarter. Finally, Strs Ohio boosted its holdings in shares of Caris Life Sciences by 301.3% in the first quarter. Strs Ohio now owns 2,179 shares of the company’s stock valued at $39,000 after acquiring an additional 1,636 shares in the last quarter.

Caris Life Sciences Trading Down 2.0%

Shares of Caris Life Sciences stock opened at $31.71 on Friday. Caris Life Sciences has a 1 year low of $14.19 and a 1 year high of $33.13. The company has a debt-to-equity ratio of 0.66, a quick ratio of 4.88 and a current ratio of 5.53. The company has a market capitalization of $8.96 billion, a P/E ratio of 88.08 and a beta of 0.86. The company’s fifty day moving average is $27.82 and its two-hundred day moving average is $21.31.

About Caris Life Sciences

Caris Life Sciences is a biotechnology and precision-medicine company that uses molecular profiling and artificial intelligence to support cancer diagnosis, treatment selection and drug development. The company analyzes tumor and blood samples to identify genomic, molecular and immune characteristics that may help physicians better understand a patient’s disease and select targeted therapies.

Its offerings include comprehensive tumor profiling, liquid-biopsy testing and data-driven clinical decision-support tools.